Betimol
- Product NDC
- 68669-522
- 11-digit product format
- 686690522
- Labeler code
- 68669
- Product ID
- 68669-522_d3344ae3-17c8-47d4-988b-e872240bffcf
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- timolol
- Dosage form
- SOLUTION
- Route
- OPHTHALMIC
- Labeler
- Vistakon Pharmaceuticals LLC
- Application
- NDA020439
- Marketing category
- NDA
- Marketing start
- 2000-10-01
- Marketing end
- 0000-00-00
- Substance
- TIMOLOL
- Active strength
- 3 mg/mL
- NDC exclude flag
- E
- Listing certified through
- 2017-12-31
- Current FDA listing
- Historical FDA.report record
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68669-522-05 | 2025-11-22 | C162847 | 48780-1 | 956f9ecf-bfa0-621f-e053-dbdaa90a74ad | 00f62dd1-dad2-4892-8a5d-21e5e54509ce |
| 68669-522-05 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-bfa0-621f-e053-dbdaa90a74ad | 00f62dd1-dad2-4892-8a5d-21e5e54509ce |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68669-522-05 | ML - Milliliter | 68669-522 | 1e07e2a0-4e10-45a8-8711-e2a32564649f | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| timolol | ACTIVE INGREDIENT | 817W3C6175 | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 | |
| timolol | ACTIVE MOIETY | 817W3C6175 | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 | |
| benzalkonium chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 | |
| sodium phosphate, dibasic, dihydrate | INACTIVE INGREDIENT | 94255I6E2T | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 | |
| sodium phosphate, monobasic, dihydrate | INACTIVE INGREDIENT | 5QWK665956 | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | BETIMOL (TIMOLOL) SOLUTION [VISTAKON PHARMACEUTICALS LLC] | 3 |